FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Bold claim of MS gene discovery comes under withering attack























APSTOCK
In MS, neurons lose their myelin coating and no longer transmit signals

Scientists are forcefully challenging a recent study that claimed to identify a rare genetic mutation that sharply boosted the risk of multiple sclerosis. The critics cite calculation errors and say they have been unable to replicate the findings — and question why the original paper was ever published in a top journal.

The withering assault has dashed hopes that the study might quickly lead to new drugs for MS and also raised questions about how such critiques are handled: like more and more journals, the one that published the paper does not run letters to the editor, making it harder for scientists to see that the claim has been hotly disputed.

As soon as the MS claim was published in June, outside scientists expressed doubts to STAT that there was really a link between the newly discovered mutation and the disease. Since then, other experts have dug into the study in greater detail, tried to replicate its findings using a database of thousands of MS patients, and checked the original paper’s statistics. In each case they concluded there is no link between the rare mutation and MS.

The study — which reported that the mutation raised the risk of MS by a whopping 70 percent — was led by Carles Vilariño-Güell of the University of British Columbia and published in the respected journal Neuron. It fingered a gene called NR1H3, finding that a rare mutation silences other genes involved in regulating inflammation or other aspects of immunity. As a result, inflammation runs wild, and the immune system destroys the protective myelin sheath on neurons, crippling their ability to carry signals needed for movement and other functions.

The purported mutation-MS link led to hopes that correcting the mutation or its downstream consequences might treat or even cure MS, which affects some 2.3 million people worldwide.

Within days, experts on MS and genetics began scrutinizing the claim.

Daniel Weeks, a professor of human genetics and biostatistics at the University of Pittsburgh, said an “extremely straightforward” analysis showed that some crucial statistical calculations in the paper were wrong. Doing them correctly “dramatically changes the strength of their claim,” he told STAT. “It’s no longer statistically significant.” That is, the association between the mutation and MS had a good likelihood of being due to chance.

Chris Cotsapas of Yale University and the Broad Institute, who studies the genetics of immune-related diseases such as MS, went further, looked for the mutation reported in the Neuron study but in different MS patients and healthy controls. Using a database maintained by the International MS Genetics Consortium, which holds information on 13 times more people than Vilariño-Güell studied, Cotsapas identified 31 people who have the mutation and also MS (out of a total sample of 32,852 MS patients in the database) and 31 who have the mutation but not the disease (out of 36,538). That is, the mutation was hardly more common in MS patients than healthy people.

Story Source: The above story is based on materials provided by STATNEWS
Note: Materials may be edited for content and length
Click here to read original article


Go to Newer News Go to Older News